Overcoming resistance to PARP inhibitor in ovarian cancer with BRCA2 reversion mutation

被引：0
|
作者：
Zouggari, Nawel [1 ,2 ]
Wang, Wenwen [3 ]
Galy, Sana Intidhar Labidi [4 ,5 ]
Halazonetis, Thanos [5 ]
机构：
[1] Fac Med, Geneva, Switzerland
[2] Univ Geneva, Fac Sci, Geneva, Switzerland
[3] Dept Med, Geneva, Switzerland
[4] Div Oncol, Geneva, Switzerland
[5] Univ Geneva, Geneva, Switzerland
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2024年 / 34卷 / SUPPL_1期
关键词：
D O I：
10.1136/ijgc-2024-ESGO.677
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
584
引用
收藏
页码：A346 / A346
页数：1
相关论文
共 50 条
  • [1] Overcoming PARP inhibitor resistance in ovarian cancer
    Pina, Pamela Soberanis
    Lheureux, Stephanie
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (03) : 364 - 376
  • [2] BRCA2 reversion mutation confers resistance to olaparib in breast cancer
    Yamamoto, Shinya
    Kawashima, Kei
    Fujiwara, Yoshie
    Adachi, Shoko
    Narui, Kazutaka
    Hosaka, Chiaki
    Takahashi, Rina
    Tsuyuki, Sho
    Sugimori, Makoto
    Tanoshima, Miki
    Sasamoto, Mahato
    Oshi, Masanori
    Yamada, Akimitsu
    Kunisaki, Chikara
    Endo, Itaru
    CLINICAL CASE REPORTS, 2023, 11 (06):
  • [3] Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance
    Pandya, Deep
    Shah, Myra
    Kaplan, Fuat
    Martino, Candice
    Levy, Gillian
    Kazanjian, Mia
    Batter, Stephen
    Martignetti, John
    Frank, Richard C.
    COLD SPRING HARBOR MOLECULAR CASE STUDIES, 2021, 7 (01):
  • [4] Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
    McMullen, Michelle
    Karakasis, Katherine
    Madariaga, Ainhoa
    Oza, Amit M.
    CANCERS, 2020, 12 (06) : 1 - 18
  • [5] Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations
    Park, Pyoung Hwa
    Yamamoto, Tomomi M.
    Li, Hua
    Alcivar, Allen L.
    Xia, Bing
    Wang, Yifan
    Bernhardy, Andrea J.
    Turner, Kristen M.
    Kossenkov, Andrew V.
    Watson, Zachary L.
    Behbakht, Kian
    Casadei, Silvia
    Swisher, Elizabeth M.
    Mischel, Paul S.
    Johnson, Neil
    Bitler, Benjamin G.
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (02) : 602 - 613
  • [6] BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer
    Pishvaian, Michael J.
    Biankin, Andrew V.
    Bailey, Peter
    Chang, David K.
    Laheru, Daniel
    Wolfgang, Christopher L.
    Brody, Jonathan R.
    BRITISH JOURNAL OF CANCER, 2017, 116 (08) : 1021 - 1026
  • [7] BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer
    Michael J Pishvaian
    Andrew V Biankin
    Peter Bailey
    David K Chang
    Daniel Laheru
    Christopher L Wolfgang
    Jonathan R Brody
    British Journal of Cancer, 2017, 116 : 1021 - 1026
  • [8] Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
    Barber, Louise J.
    Sandhu, Shahneen
    Chen, Lina
    Campbell, James
    Kozarewa, Iwanka
    Fenwick, Kerry
    Assiotis, Ioannis
    Rodrigues, Daniel Nava
    Reis Filho, Jorge S.
    Moreno, Victor
    Mateo, Joaquin
    Molife, L. Rhoda
    De Bono, Johann
    Kaye, Stan
    Lord, Christopher J.
    Ashworth, Alan
    JOURNAL OF PATHOLOGY, 2013, 229 (03): : 422 - 429
  • [9] Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?
    Ray-Coquard, Isabelle
    Vanacker, Helene
    Le Saux, Olivia
    Tredan, Olivier
    EBIOMEDICINE, 2020, 61
  • [10] Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer
    Huang, Tzu-Ting
    Burkett, Sandra Sczerba
    Tandon, Mayank
    Yamamoto, Tomomi M.
    Gupta, Nitasha
    Bitler, Benjamin G.
    Lee, Jung-Min
    Nair, Jayakumar R.
    ONCOGENE, 2022, 41 (46) : 5020 - 5031
12345